KLRA earnings: real EPS beat/miss history, P/E -14.12. Updated 2026-07-23.
Kailera Therapeutics (KLRA) Research Hub
Kailera Therapeutics (KLRA) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 13.94 USD (-6.06%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -14.12, market cap 2.36B. This hub links to the full technical, earnings and options research available for KLRA.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 13.94 USD (-6.06%) |
| 52-week range | 13.9 USD – 23.82 USD |
| Trend regime | Range |
| 14-day RSI | 27.6 (Oversold) |
| Trailing P/E | -14.12 |
| Market cap | 2.36B |
| Dividend yield | 0.00% |
Available research for KLRA
Covered Call on KLRA: how it works, illustrative setup around the real 13.94 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on KLRA: how it works, illustrative setup around the real 13.94 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on KLRA: how it works, illustrative setup around the real 13.94 USD price, max profit/loss, breakeven and when to use it. Educational.
KLRA technical analysis: range, last 13.94 USD, RSI 27.6, 52w range 13.9 USD–23.82 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is KLRA in?
Kailera Therapeutics (KLRA) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is KLRA in an uptrend or downtrend?
As of 2026-09-11, KLRA is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is KLRA's trailing P/E ratio?
KLRA's trailing P/E is -14.12, with a market cap of 2.36B. See the earnings research page for full valuation detail.